Pfizer Reports Decent Second Quarter Results; Plans to Spin Off Animal Health Business
publication date: Jul 31, 2012
Pfizer posted decent second-quarter results that showed strong cost containment in the face of declining sales of its blockbuster drug Lipitor. The company also announced plans to spin off its animal health business to focus on its core pharma business. We maintain our view that Pfizer is significantly underpriced.
To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.